Nie Wenbo, Xu Ping, Hao Chunyan, Chen Yingying, Yin Yanling, Wang Lisheng
School of Nursing, Jilin University.
Gynecology and Integrated Care Unit, China-Japan Union Hospital of Jilin University.
Medicine (Baltimore). 2020 May;99(19):e19881. doi: 10.1097/MD.0000000000019881.
Primary dysmenorrhea is common and troublesome. The comparative efficacy of over-the-counter analgesics (OTCAs) for dysmenorrhea is unclear. This study was aimed at conducting a network meta-analysis to assess the efficacy and safety of 5 OTCAs - naproxen, ibuprofen,diclofenac, aspirin, and ketoprofen - in patients with primary dysmenorrhea.
The study was registered with PROSPERO (number: CRD42019133556). The search strategy involved a review of PubMed, Embase, Cochrane Library, Web of Science, and CINAHL for relative randomized controlled trials of the 5 analgesics from the date of database establishment to July 2019. The outputs are presented as odds ratios (ORs), their corresponding 95% confidence intervals (CIs), and the surface under the cumulative ranking area (SUCRA) probabilities.
Thirty-five trials with 4383 participants were included in our study. As for efficacy outcomes, all the included analgesics except aspirin were more effective than placebo in treating dysmenorrhea [naproxen (OR 3.99, 95% CI 2.18-7.30), ibuprofen (OR 10.08, 95% CI 3.29-30.85), diclofenac (OR 11.82, 95% CI 2.66-52.48), and ketoprofen (OR 5.12, 95% CI 1.57-16.69). The OTCAs were superior to the placebo in terms of pain relief in primary dysmenorrhea. Aspirin was less effective than ibuprofen (OR 0.17, 95% CI 0.04-0.73) and diclofenac (OR 1.17, 95% CI 0.02-0.85). The SUCRA curves showed that diclofenac and ibuprofen were the most and second most effective (85.1% and 83.8%, respectively), followed by ketoprofen, naproxen, and aspirin. Regarding safety, there was no significant difference between the 5 OTCAs included and the placebo. Diclofenac versus ibuprofen (OR 4.31, 95% CI 1.18-15.67), ketoprofen versus diclofenac (OR 0.18, 95% CI 0.04-0.78), and ketoprofen versus aspirin (OR 0.41, 95% CI 0.18-0.97) presented statistically significant differences. Ketoprofen and ibuprofen were ranked the best (SUCRA 90.6% and 79.6%), followed by naproxen, aspirin, and diclofenac.
Considering the efficacy and safety, ibuprofen is recommended as the optimal OTCA for primary dysmenorrhea. Further well-designed studies that directly compare these analgesics are needed to support our conclusion.
原发性痛经很常见且令人困扰。非处方镇痛药(OTCAs)治疗痛经的相对疗效尚不清楚。本研究旨在进行一项网状Meta分析,以评估5种非处方镇痛药——萘普生、布洛芬、双氯芬酸、阿司匹林和酮洛芬——对原发性痛经患者的疗效和安全性。
该研究已在国际前瞻性注册系统(PROSPERO)注册(注册号:CRD42019133556)。检索策略包括对PubMed、Embase、Cochrane图书馆、科学网和护理学与健康领域数据库(CINAHL)进行检索,以查找从数据库建立之日至2019年7月这5种镇痛药的相关随机对照试验。结果以比值比(OR)、其相应的95%置信区间(CI)以及累积排序曲线下面积(SUCRA)概率表示。
本研究纳入了35项试验,共4383名参与者。在疗效结果方面,除阿司匹林外,所有纳入的镇痛药在治疗痛经方面均比安慰剂更有效[萘普生(OR 3.99,95%CI 2.18 - 7.30)、布洛芬(OR 10.08,95%CI 3.29 - 30.85)、双氯芬酸(OR 11.82,95%CI 2.66 - 52.48)和酮洛芬(OR 5.12,95%CI 1.57 - 16.69)]。非处方镇痛药在缓解原发性痛经疼痛方面优于安慰剂。阿司匹林比布洛芬(OR 0.17,95%CI 0.04 - 0.73)和双氯芬酸(OR 1.17,95%CI 0.02 - 0.85)效果更差。SUCRA曲线显示双氯芬酸和布洛芬是最有效和第二有效的药物(分别为85.1%和83.8%),其次是酮洛芬、萘普生和阿司匹林。在安全性方面,纳入的5种非处方镇痛药与安慰剂之间无显著差异。双氯芬酸与布洛芬(OR 4.31,95%CI 1.18 - 15.67)、酮洛芬与双氯芬酸(OR 0.18,95%CI 0.04 - 0.78)以及酮洛芬与阿司匹林(OR 0.41,95%CI 0.18 - 0.97)之间存在统计学显著差异。酮洛芬和布洛芬排名最佳(SUCRA分别为90.6%和79.6%),其次是萘普生、阿司匹林和双氯芬酸。
考虑到疗效和安全性,推荐布洛芬作为原发性痛经的最佳非处方镇痛药。需要进一步设计良好的直接比较这些镇痛药的研究来支持我们的结论。